ClinicalTrials.gg
Not yet recruitingNCT07950839SHG vs LCUpdated Nov 20, 2026

Sodium Hyaluronate Gel Versus Lidocaine Cream for Endotracheal Tube Lubrication

An interventional study of Medical sodium hyaluronate lubricating gel and Lidocaine Cream 5% in Postoperative Throat Numbness; Post-intubation Throat Symptoms, sponsored by Beijing Tsinghua Chang Gung Hospital. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Beijing Tsinghua Chang Gung Hospital · Not applicable, Interventional, and Prevention

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study is a prospective, randomized, single-blind, parallel-group, single-center clinical trial in adults undergoing elective laparoscopic surgery under general anesthesia with endotracheal intubation. It will compare sterile medical sodium hyaluronate gel with lidocaine cream as a lubricant applied to the distal portion and cuff surface of the endotracheal tube. The study aims to evaluate whether sodium hyaluronate gel is superior to lidocaine cream in reducing postoperative throat numbness. The primary outcome is throat numbness assessed using a visual analog scale (VAS) 30 minutes after surgery. Secondary outcomes include throat numbness at other specified time points, coughing during emergence and after the first oral water intake, postoperative sore throat, hoarseness, endotracheal tube cuff pressure, hemodynamic responses during intubation and extubation, satisfaction, and adverse events. A total of 120 participants are planned, with 60 participants in each group.

02

Conditions studied

  • Postoperative Throat Numbness; Post-intubation Throat Symptoms

Browse trials for

Keywords

  • Sodium hyaluronate gel
  • lidocaine cream
  • endotracheal intubation
  • postoperative throat numbness
  • postoperative sore throat
  • hoarseness
  • laparoscopic surgery
  • general anesthesia
  • randomized controlled trial
03

In context

Hoarseness

54 studies on the registry are indexed under Hoarseness; 11 are open to participants now.

This study's planned enrollment of 120 is close to the median of 115 across 46 interventional studies indexed under Hoarseness.

Browse Hoarseness studies →

Lead sponsor

Beijing Tsinghua Chang Gung Hospital is the lead sponsor of 114 studies on the registry; 61 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 to 65 years, of either sex.
  • (ASA) physical status I or II.
  • Patients scheduled for elective laparoscopic surgery under general anesthesia with endotracheal intubation.
  • Expected surgical duration of 1 to 4 hours.
  • Able to understand the study and provide written .

Exclusion criteria

Exclusion Criteria:

  • Patients expected to be transferred to the intensive care unit (ICU) postoperatively.
  • Known or anticipated difficult airway.
  • History of severe respiratory disease, such as asthma or .
  • High risk of gastroesophageal reflux or aspiration, including a full stomach or a history of severe gastroesophageal reflux disease.
  • Known allergy to sodium hyaluronate, lidocaine, or any other study-related medication/product.
  • Pre-existing sore throat or hoarseness before surgery.
  • Pregnancy or breastfeeding.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Medical sodium hyaluronate lubricating gel

    A volume of 2-3 mL of sterile medical sodium hyaluronate lubricating gel (manufacturer identified in the protocol as Bloomage Biotechnology) will be evenly applied to the distal end and cuff surface of the endotracheal tube before intubation.

    Combination Product: Medical sodium hyaluronate lubricating gel

  • Active comparator
    Lidocaine cream

    A volume of 2-3 mL of lidocaine cream will be evenly applied to the distal end and cuff surface of the endotracheal tube before intubation.

    Drug: Lidocaine Cream 5%

Interventions

  • Combination productMedical sodium hyaluronate lubricating gel

    A volume of 2-3 mL of sterile medical sodium hyaluronate lubricating gel (manufacturer identified in the protocol as Bloomage Biotechnology) will be evenly applied to the distal end and cuff surface of the endotracheal tube before intubation. The protocol lists medical device registration certificate number

  • DrugLidocaineStudies of LidocaineLidocaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A volume of 2-3 mL of lidocaine cream will be evenly applied to the distal end and cuff surface of the endotracheal tube before intubation.

06

What researchers measure

Primary outcomes

  1. Throat numbness intensity

    Throat numbness intensity will be assessed using the 11-point Visual Analogue Scale (VAS), ranging from 0 to 10. A score of 0 indicates no throat numbness, whereas a score of 10 indicates the most severe imaginable throat numbness. Higher scores indicate more severe throat numbness.

    Time frame: 30 minutes after extubation

Secondary outcomes

  1. Throat numbness intensity

    Throat numbness intensity will be assessed using the 11-point Visual Analogue Scale (VAS), ranging from 0 to 10. A score of 0 indicates no throat numbness, whereas a score of 10 indicates the most severe imaginable throat numbness. Higher scores indicate more severe throat numbness.

    Time frame: Immediately after extubation, 1 hour, 8 hours, 16 hours, and 24 hours.

  2. Time to first oral water intake and incidence of coughing during the first water intake

    The time from extubation to the first oral water intake will be recorded in minutes. The occurrence of coughing during the first water intake will also be recorded.

    Time frame: From extubation to the first oral water intake, within 24 hours after extubation.

  3. Severity of coughing during emergence from general anesthesia

    Coughing during emergence and extubation will be graded as follows: 0 = no cough; 1 = mild, single cough; 2 = moderate, more than one cough with a duration of less than 5 seconds; 3 = severe, cough lasting more than 5 seconds. Suctioning during emergence will be recorded. No routine suctioning will be performed at extubation or during the first 5 minutes after extubation, unless clinically required.

    Time frame: During emergence from general anesthesia, from the end of anesthesia to 5 minutes after extubation.

  4. Postoperative sore throat severity

    Postoperative sore throat severity will be assessed using the 11-point Visual Analogue Scale (VAS), ranging from 0 to 10. A score of 0 indicates no sore throat, whereas a score of 10 indicates the most severe imaginable postoperative sore throat. Higher scores indicate more severe sore throat.

    Time frame: Immediately after extubation, and at 30 minutes, 1 hour, 8 hours, 16 hours, and 24 hours after extubation.

  5. Postoperative hoarseness severity

    Postoperative hoarseness severity will be assessed using the 11-point Visual Analogue Scale (VAS), ranging from 0 to 10. A score of 0 indicates no hoarseness , whereas a score of 10 indicates the most severe imaginable postoperative sore throat. Higher scores indicate more severe hoarseness .

    Time frame: Immediately after extubation, and at 30 minutes, 1 hour, 8 hours, 16 hours, and 24 hours after extubation.

  6. Endotracheal tube cuff pressure measured in cmH₂O

    Endotracheal tube cuff pressure will be measured using a cuff pressure manometer. The pressure will be recorded in cmH₂O.

    Time frame: At 1, 2, and 3 hours after intubation, and immediately before extubation.

  7. Incidence of hemodynamic abnormalities assessed by heart rate and blood pressure measurements

    Heart rate (HR), systolic blood pressure (SBP), and diastolic blood pressure (DBP) will be monitored and recorded. Hemodynamic abnormalities are defined as HR greater than 100 beats/min or less than 60 beats/min; SBP ≥140 mmHg and/or DBP ≥90 mmHg; or a decrease in SBP of more than 20% from baseline.

    Time frame: During tracheal extubation

  8. Anesthesiologists' satisfaction with the assigned endotracheal tube lubricant

    Anesthesiologists' satisfaction with the assigned lubricant will be evaluated using a 5-point Likert scale, with scores ranging from 1 (very dissatisfied) to 5 (very satisfied). Higher scores indicate greater satisfaction.

    Time frame: Immediately after tracheal intubation.

  9. Patient satisfaction with the anesthesia recovery process

    Patient satisfaction with the anesthesia recovery process will be assessed using a 5-point Likert scale during the PACU stay. Scores range from 1 (very dissatisfied) to 5 (very satisfied), with higher scores indicating greater satisfaction.

    Time frame: Within 2 hours after completion of surgery, during the post-anesthesia care unit (PACU) stay and before PACU discharge.

  10. Incidence of adverse events associated with the study interventions

    The occurrence of adverse events, including allergic reactions, laryngospasm, aspiration, nausea, and vomiting, will be recorded and compared between the two groups.

    Time frame: From administration of the assigned lubricant until 24 hours after extubation.

07

Study locations

No study locations are listed for this record.

08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Mar 2027, 4 months later.

Of 21 interventional studies with no phase under Hoarseness, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's planned 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2026
First posted
Nov 20, 2026
StartEst.
Nov 4, 2026
Primary completionEst.
Mar 4, 2027
CompletionEst.
Mar 10, 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07950839
Responsible party
Yi Duan (Professor, Beijing Tsinghua Chang Gung Hospital) — Principal investigator
First posted
Nov 20, 2026
Start date
Nov 4, 2026 (estimated)
Primary completion
Mar 4, 2027 (estimated)
Completion
Mar 10, 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Fan Xueyan Fan
Contact
fxya05413@btch.edu.cn
+86 19801288101

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion